Copyright © 2002 by the European Society of Cardiology.
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy
a Institute for Cardiovascular Research, University of Leeds, U.K.
b Robertson Centre for Biostatistics, University of Glasgow, U.K.
revised September 18, 2001; accepted September 21, 2001
Abstract
Aims The Glycine389 variant of the beta-1 adrenergic receptor generates markedly less cAMP when stimulated in vitro than the more prevalent Arginine389 variant and may confer protection against coronary events similar to that observed with beta-blockers. The aim of this study was to ascertain whether this Glycine389 variant protects against coronary events.
Methods and Results We identified the genotype at position 389 of the ß1AR in 1554 individuals taken from men enrolled in the West of Scotland Coronary Prevention Study. Men with a coronary event (event group) were each matched for age and smoking status with two control subjects from the same cohort who had not had a coronary event (control group). We compared the distribution of genotypes in the event and control groups. Conditional logistic regression was used to calculate odds ratios for each of the genotypes. The prevalence of the three genotypes in the entire cohort was ArgArg 53.5%, ArgGly 39.6%, GlyGly 6.9%. The Arg389Gly beta-1 adrenergic receptor polymorphism was not associated with coronary events. Using the ArgArg genotype as the reference, the odds ratio for the ArgGly genotype was 1·1 (95% CI, 0·88–1·38) and for the GlyGly genotype it was 1·05 (95% CI, 0·68–1·62).
Conclusion Our longitudinal case-control study demonstrates that the Glycine389 variant of the beta-1 adrenergic receptor does not protect against coronary events. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.
Key Words: Beta-1 adrenergic receptor, polymorphism, myocardial infarction
f1 Correspondence: Hazel L. White, Institute for Cardiovascular Research, University of Leeds, U.K.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Amisten, O. Melander, A.-K. Wihlborg, G. Berglund, and D. Erlinge Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriersof the Thr-87 variant of the ATP receptor P2Y11 Eur. Heart J., January 1, 2007; 28(1): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Kirstein and P. A. Insel Autonomic Nervous System Pharmacogenomics: A Progress Report Pharmacol. Rev., March 1, 2004; 56(1): 31 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Lohse, S. Engelhardt, and T. Eschenhagen What Is the Role of {beta}-Adrenergic Signaling in Heart Failure? Circ. Res., November 14, 2003; 93(10): 896 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 On behalf of the MERIT-HF Study Group, H. L. White, R. A. de Boer, A. Maqbool, D. Greenwood, D. J. van Veldhuisen, R. Cuthbert, S. G. Ball, A. S. Hall, and A. J. Balmforth An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study Eur J Heart Fail, August 1, 2003; 5(4): 463 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jones and H. Montgomery The Gly389Arg beta-1 adrenoceptor polymorphism and cardiovascular disease: time for a rethink in the funding of genetic studies? Eur. Heart J., July 2, 2002; 23(14): 1071 - 1074. [Full Text] [PDF]
|
|